

MYLIP Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP5315c

Specification

MYLIP Antibody (Center) - Product Information

Application	WB, FC, IHC-P,E
Primary Accession	Q8WY64
Other Accession	NP_037394
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Antigen Region	111-139

MYLIP Antibody (Center) - Additional Information

Gene ID 29116

Other Names

E3 ubiquitin-protein ligase MYLIP, 632-, Inducible degrader of the LDL-receptor, Idol, Myosin regulatory light chain interacting protein, MIR, MYLIP, BZF1, IDOL

Target/Specificity

This MYLIP antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 111-139 amino acids from the Central region of human MYLIP.

Dilution

WB~~1:2000

FC~~1:10~50

IHC-P~~1:50~100

E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

MYLIP Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

MYLIP Antibody (Center) - Protein Information

Name MYLIP

Synonyms BZF1, IDOL

Function E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR.

Cellular Location

Cytoplasm. Cell membrane; Peripheral membrane protein


Tissue Location

Ubiquitously expressed.



MYLIP Antibody (Center) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


MYLIP Antibody (Center) - Images

MYLIP Antibody (Center T126) (Cat. #AP5315c) western blot analysis in mouse heart tissue lysates (35ug/lane). This demonstrates the MYLIP antibody detected the MYLIP protein (arrow).






Anti-MYLIP Antibody (Center) at 1:2000 dilution + Rat brain lysate Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 50 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



MYLIP antibody (Center) (Cat. #AP5315c) immunohistochemistry analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the MYLIP antibody (Center) for immunohistochemistry. Clinical relevance has not been evaluated.



MYLIP Antibody (Center) (Cat. #AP5315c) flow cytometric analysis of MCF-7 cells (right histogram) compared to a negative control cell (left histogram). FITC-conjugated goat-anti-rabbit

secondary antibodies were used for the analysis.

MYLIP Antibody (Center) - Background

The ERM protein family members ezrin, radixin, and moesin are cytoskeletal effector proteins linking actin to membrane-bound proteins at the cell surface. Myosin regulatory light chain interacting protein (MYLIP) is a novel ERM-like protein that interacts with myosin regulatory light chain and inhibits neurite outgrowth.

MYLIP Antibody (Center) - References

Chasman, D.I., et al. PLoS Genet. 5 (11), E1000730 (2009)
Lindholm, D., et al. Cell. Mol. Life Sci. 66(21):3399-3402(2009)
Zelcer, N., et al. Science 325(5936):100-104(2009)